Background: More than 50% of American adolescents and adults report having used illicit drugs in their lifetime. We examined the association of lifetime opiate and cocaine use with reduced kidney function, albuminuria and rapid kidney function decline among urban-dwelling adults. Methods: Our prospective cohort included 2,286 Healthy Aging in Neighborhoods of Diversity across the Life Span study participants who were community-dwelling adults residing in Baltimore, MD. The predictive variables were lifetime opiate and cocaine use, defined as use of opiates or crack/cocaine ≥5 times. Outcomes included prevalent reduced estimated glomerular filtration rate (eGFR; <60 ml/min/1.73 m2 by Chronic Kidney Disease (CKD)-Epidemiology Collaboration), albuminuria (albumin-to-creatinine ratio >30 mg/g, n = 1,652) and rapid kidney function decline (>3 ml/min/1.73 m2 per year over a median of 4.7 years, n = 1,660). Results: Participants' mean age was 48 years, 15% reported opiate use, and 22% reported cocaine use. A total of 115 (5.0%) participants had reduced eGFR, 190 (11.5%) had albuminuria and 230 (13.8%) experienced rapid decline in kidney function. In adjusted logistic regression analyses, both substances were associated with greater odds of reduced eGFR (OR 2.71, 95% CI 1.50-4.89 for opiates; OR 1.40, 95% CI 0.87-2.24 for cocaine). Both substances were associated with greater odds of albuminuria (OR 1.20, 95% CI 0.83-1.73 for opiates; OR 1.80, 95% CI 1.29-2.51 for cocaine). Neither substance was associated with the rapid decline of kidney function. Conclusions: Lifetime opiate and cocaine use was associated with prevalent reduced eGFR and albuminuria, yet not with rapid kidney function decline. The use of opiate and cocaine may be an important risk factor for CKD in urban populations.

Keywords:
Epidemiology, Chronic kidney disease, Substance abuse, Cocaine, Opiates
1.
Center for Behavioral Health Statistics and Quality: 2014 National Survey on Drug Use and Health: Detailed Tables. Rockville, Substance Abuse and Mental Health Services Administration, 2015.
2.
Substance Abuse and Mental Health Services Administration. Behavioral Health Barometer: Maryland, 2014. HHS Publication No. SMA-15-4895MD. Rockville, Substance Abuse and Mental Health Services Administration, 2015.
3.
Maryland Department of Health and Mental Hygiene. Drug and Alcohol Related Intoxication Deaths in Maryland, 2014. http://bha.dhmh.maryland.gov/OVERDOSE_PREVENTION/Documents/2015.05.19%20-%20Annual%20OD%20Report%202014_merged%20file%20final.pdf.
4.
Behavioral Health System Baltimore. Baltimore Mayor's Heroin Treatment & Prevention Task Force, 2015. http://health.baltimorecity.gov/sites/default/files/Mayor%20Heroin%20Treatment%20Prevention%20Task%20Force%20Final%20Report%20July%2013%202015.pdf.
5.
National Center for Statistics and Analysis: 2013 Motor Vehicle Crashes: Overview. (Traffic Safety Facts Research Note. Report No. DOT HS 812 101). Washington, National Highway Traffic Safety Administration, 2014.
6.
US Renal Data System: USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
7.
Akkina SK, Ricardo AC, Patel A, Das A, Bazzano LA, Brecklin C, et al: Illicit drug use, hypertension, and chronic kidney disease in the US adult population. Transl Res 2012;160:391-398.
8.
Vupputuri S, Batuman V, Muntner P, Bazzano LA, Lefante JJ, Whelton PK, et al: The risk for mild kidney function decline associated with illicit drug use among hypertensive men. Am J Kidney Dis 2004;43:629-635.
9.
Evans MK, Lepkowski JM, Powe NR, LaVeist T, Kuczmarski MF, Zonderman AB: Healthy aging in neighborhoods of diversity across the life span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status. Ethn Dis 2010;20:267-275.
10.
Crews DC, Kuczmarski MF, Grubbs V, Hedgeman E, Shahinian VB, Evans MK, et al: Effect of food insecurity on chronic kidney disease in lower-income Americans. Am J Nephrol 2014;39:27-35.
11.
Crews DC, Kuczmarski MF, Miller ER 3rd, Zonderman AB, Evans MK, Powe NR: Dietary habits, poverty, and chronic kidney disease in an urban population. J Ren Nutr 2015;25:103-110.
12.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al: A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
13.
Hiramoto JS, Katz R, Peralta CA, Ix JH, Fried L, Cushman M, et al: Inflammation and coagulation markers and kidney function decline: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis 2012;60:225-232.
14.
Perneger TV, Klag MJ, Whelton PK: Recreational drug use: a neglected risk factor for end-stage renal disease. Am J Kidney Dis 2001;38:49-56.
15.
Norris KC, Thornhill-Joynes M, Robinson C, Strickland T, Alperson BL, Witana SC, et al: Cocaine use, hypertension, and end-stage renal disease. Am J Kidney Dis 2001;38:523-528.
16.
Jaffe JA, Kimmel PL: Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006;1:655-667.
17.
Nzerue CM, Hewan-Lowe K, Riley LJ Jr: Cocaine and the kidney: a synthesis of pathophysiologic and clinical perspectives. Am J Kidney Dis 2000;35:783-795.
18.
Chiueh CC, Kopin IJ: Centrally mediated release by cocaine of endogenous epinephrine and norepinephrine from the sympathoadrenal medullary system of unanesthetized rats. J Pharmacol Exp Ther 1978;205:148-154.
19.
Kon V, Yoshioka T, Fogo A, Ichikawa I: Glomerular actions of endothelin in vivo. J Clin Invest 1989;83:1762-1767.
20.
Hendricks-Munoz KD, Gerrets RP, Higgins RD, Munoz JL, Caines VV: Cocaine-stimulated endothelin-1 release is decreased by angiotensin-converting enzyme inhibitors in cultured endothelial cells. Cardiovasc Res 1996;31:117-123.
21.
Mo W, Singh AK, Arruda JA, Dunea G: Role of nitric oxide in cocaine-induced acute hypertension. Am J Hypertens 1998;11(6 pt 1):708-714.
22.
Palamara AT, Di Francesco P, Ciriolo MR, Buè C, Lafavia E, Rotilio G, et al: Cocaine increases Sendai virus replication in cultured epithelial cells: critical role of the intracellular redox status. Biochem Biophys Res Commun 1996;228:579-585.
23.
Barroso-Moguel R, Mendez-Armenta M, Villeda-Hernandez J: Experimental nephropathy by chronic administration of cocaine in rats. Toxicology 1995;98:41-46.
24.
Di Paolo N, Fineschi V, Di Paolo M, Wetly CV, Garosi G, Del Vecchio MT, et al: Kidney vascular damage and cocaine. Clin Nephrol 1997;47:298-303.
25.
Singhal PC, Gibbons N, Abramovici M: Long term effects of morphine on mesangial cell proliferation and matrix synthesis. Kidney Int 1992;41:1560-1570.
26.
Singhal PC, Pamarthi M, Shah R, Chandra D, Gibbons N: Morphine stimulates superoxide formation by glomerular mesangial cells. Inflammation 1994;18:293-299.
27.
Singhal PC, Pan CQ, Sagar S, Gibbons N, Valderrama E: Morphine enhances deposition of ferritin-antiferritin complexes in the glomerular mesangium. Nephron 1995;70:229-234.
28.
Singhal PC, Mattana J, Garg P, Arya M, Shan Z, Gibbons N, et al: Morphine-induced macrophage activity modulates mesangial cell proliferation and matrix synthesis. Kidney Int 1996;49:94-102.
29.
Singhal PC, Sharma P, Kapasi AA, Reddy K, Franki N, Gibbons N: Morphine enhances macrophage apoptosis. J Immunol 1998;160:1886-1893.
30.
Singhal PC, Sharma P, Sanwal V, Prasad A, Kapasi A, Ranjan R, et al: Morphine modulates proliferation of kidney fibroblasts. Kidney Int 1998;53:350-357.
31.
Patel K, Bhaskaran M, Dani D, Reddy K, Singhal PC: Role of heme oxygenase-1 in morphine-modulated apoptosis and migration of macrophages. J Infect Dis 2003;187:47-54.
32.
Sharp BM, Keane WF, Suh HJ, Gekker G, Tsukayama D, Peterson PK: Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages. Endocrinology 1985;117:793-795.
33.
Maines MD: Heme oxygenase: function, multiplicity, regulatory mechanisms, and clinical applications. FASEB J 1988;2:2557-2568.
34.
Garg L, Gupta S, Swami A, Zhang P: Levamisole/cocaine induced systemic vasculitis and immune complex glomerulonephritis. Case Rep Nephrol 2015;2015:372413.
35.
Neugarten J, Gallo GR, Buxbaum J, Katz LA, Rubenstein J, Baldwin DS: Amyloidosis in subcutaneous heroin abusers (‘skin poppers' amyloidosis'). Am J Med 1986;81:635-640.
36.
Crowley S, Feinfeld DA, Janis R: Resolution of nephrotic syndrome and lack of progression of heroin-associated renal amyloidosis. Am J Kidney Dis 1989;13:333-335.
37.
Dubrow A, Mittman N, Ghali V, Flamenbaum W: The changing spectrum of heroin-associated nephropathy. Am J Kidney Dis 1985;5:36-41.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.